AN2 Therapeutics Valuation
| ANTX Stock | USD 1.12 0.05 4.67% |
Today, the firm appears to be undervalued. AN2 Therapeutics owns a latest Real Value of $1.45 per share. The recent price of the firm is $1.12. Our model approximates the value of AN2 Therapeutics from evaluating the firm fundamentals such as Shares Owned By Institutions of 46.30 %, price to book of 0.38 X, and Return On Asset of -0.32 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting AN2 Therapeutics' valuation include:
Undervalued
Today
Please note that AN2 Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of AN2 Therapeutics is based on 3 months time horizon. Increasing AN2 Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since AN2 Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AN2 Stock. However, AN2 Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.12 | Real 1.45 | Target 2.67 | Hype 1.12 | Naive 1.2 |
The intrinsic value of AN2 Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AN2 Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AN2 Therapeutics helps investors to forecast how AN2 stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AN2 Therapeutics more accurately as focusing exclusively on AN2 Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use AN2 Therapeutics' intrinsic value based on its ongoing forecasts of AN2 Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against AN2 Therapeutics' closest peers.
AN2 Therapeutics Cash |
|
AN2 Valuation Trend
Analysing the historical paterns of AN2 Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of AN2 Therapeutics over time and is usually enough for investors to make rational market timing decisions.
AN2 Therapeutics Total Value Analysis
AN2 Therapeutics is presently anticipated to have valuation of (61.78 M) with market capitalization of 33.46 M, debt of 14.04 M, and cash on hands of 113.39 M. The negative valuation of AN2 Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the AN2 Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(61.78 M) | 33.46 M | 14.04 M | 113.39 M |
AN2 Therapeutics Asset Utilization
One of the ways to look at asset utilization of AN2 is to check how much profit was generated for every dollar of assets it reports. AN2 Therapeutics owns a negative utilization of current and long term assets of -0.32 %, losing $0.003219 for each dollar of current and long term assets held by the firm. Discouraging asset utilization signifies that the company is being less competent with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of AN2 Therapeutics shows how wasteful it operates for each dollar spent on its current and long term assets.AN2 Therapeutics Ownership Allocation
AN2 Therapeutics secures a total of 29.88 Million outstanding shares. 30% of AN2 Therapeutics outstanding shares are owned by institutions. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Hence, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.AN2 Therapeutics Profitability Analysis
Net Loss for the year was (64.73 M) with profit before overhead, payroll, taxes, and interest of 0.About AN2 Therapeutics Valuation
Our relative valuation model uses a comparative analysis of AN2 Therapeutics. We calculate exposure to AN2 Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AN2 Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -69.3 K | -72.8 K |
AN2 Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 23.6 M |
AN2 Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of AN2 Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value AN2 we look at many different elements of the entity such as AN2's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as AN2 Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use AN2 Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes AN2 Therapeutics' worth.Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.